QQQ0.14%

Trending

SPCE33.88%

home Symbol AARDnews

AARD
Aardvark Therapeutics Inc

122

Mkt Cap

$91.63M

Volume

76,409.00

52W High

$17.94

52W Low

$3.35

PE Ratio

-1.31

AARD Fundamentals

Price

$4.19

Prev Close

$4.20

Open

$4.17

50D MA

$4.77

Beta

1.69

Avg. Volume

171,405.11

EPS (Annual)

-$2.64

P/B

1.05

Rev/Employee

$0.00

$176.74

Info

News

all

press releases

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire SAN FRANCISCO, May 28, 2026 SAN FRANCISCO, May 28, 2026...

PR Newswire

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026...

PR Newswire

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On...

PR Newswire

AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage

Following a clinical hold on its lead drug candidate, multiple brokerages downgraded and cut AARD’s price target.

Stocktwits

FDA Halts Aardvark Therapeutics Rare Disease Study

FDA places full clinical hold on Aardvark's ARD-101 studies as the company reviews Phase 3 safety and efficacy data.read more...

Benzinga

AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program

Aardvark Therapeutics said the FDA’s full clinical hold applies to the ongoing late-stage HERO trial for hyperphagia in PWS patients and the associated open-label extension (OLE) study.

Stocktwits

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On...

PR Newswire

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a...

MarketBeat

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On...

PR Newswire

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Large Decline in Short Interest

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,132,986...

MarketBeat

...